Literature DB >> 17911127

Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research.

Kalipso Chalkidou1, Andrew Hoy, Peter Littlejohns.   

Abstract

Mesh：

Year:  2007        PMID： 17911127      PMCID： PMC1997271          DOI： 10.1177/014107680710001013

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  18 in total

1.  Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months.

Authors:  Phil Edwards; Miguel Arango; Laura Balica; Rowland Cottingham; Hesham El-Sayed; Barbara Farrell; Janice Fernandes; Tamar Gogichaisvili; Nyoman Golden; Bennie Hartzenberg; Mazhar Husain; Mario Izurieta Ulloa; Zouheir Jerbi; Hussein Khamis; Edward Komolafe; Véronique Laloë; Gabrielle Lomas; Silke Ludwig; Guy Mazairac; Maria de los Angeles Muñoz Sanchéz; Luis Nasi; Fatos Olldashi; Patrick Plunkett; Ian Roberts; Peter Sandercock; Haleema Shakur; Caridad Soler; Reto Stocker; Petr Svoboda; Stefan Trenkler; N K Venkataramana; Jonathan Wasserberg; David Yates; Surakrant Yutthakasemsunt
Journal:  Lancet       Date:  2005 Jun 4-10       Impact factor: 79.321

2.  Questions about adjuvant trastuzumab still remain.

Authors:  Daniel Hind; Hazel Pilgrim; Sue Ward
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

3.  Association of study type, sample size, and follow-up length with type of recommendation produced by the National Institute for Health and Clinical Excellence Interventional Procedures Programme.

Authors:  William Bruce Campbell; Steven J Barnes; Rebecca A Kirby; Sarah L Willett; Sally Wortley; Georgios Lyratzopoulos
Journal:  Int J Technol Assess Health Care       Date:  2007       Impact factor: 2.188

4.  Coverage options for promising technologies: Medicare's 'coverage with evidence development'.

Authors:  Sean R Tunis; Steven D Pearson
Journal:  Health Aff (Millwood)       Date:  2006 Sep-Oct       Impact factor: 6.301

5.  Medicare's requirement for research participation as a condition of coverage: is it ethical?

Authors:  Steven D Pearson; Franklin G Miller; Ezekiel J Emanuel
Journal:  JAMA       Date:  2006-08-23       Impact factor: 56.272

6.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors:  Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

7.  Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group.

Authors:  Ambuj Kumar; Heloisa Soares; Robert Wells; Mike Clarke; Iztok Hozo; Archie Bleyer; Gregory Reaman; Iain Chalmers; Benjamin Djulbegovic
Journal:  BMJ       Date:  2005-11-18

8.  Using clinical trials as a condition of coverage: lessons from the National Emphysema Treatment Trial.

Authors:  Tanisha Carino; Steven Sheingold; Sean Tunis
Journal:  Clin Trials       Date:  2004-02       Impact factor: 2.486

9.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

10.  Cost-effectiveness of neonatal extracorporeal membrane oxygenation based on 7-year results from the United Kingdom Collaborative ECMO Trial.

Authors:  Stavros Petrou; Matthias Bischof; Charlotte Bennett; Diana Elbourne; David Field; Helena McNally
Journal:  Pediatrics       Date:  2006-05       Impact factor: 7.124
View more
  9 in total

Review 1.  Using comparative effectiveness research to inform policy and practice in the UK HHS: past, present and future.

Authors:  Kalipso Chalkidou; Tom Walley
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Addressing uncertainties about the effects of treatments offered to NHS patients: whose responsibility?

Authors:  Iain Chalmers
Journal:  J R Soc Med       Date:  2007-10       Impact factor: 5.344

3.  NICE: managing conflict.

Authors:  Steve Iliffe; Jill Manthorpe
Journal:  J R Soc Med       Date:  2008-01       Impact factor: 5.344

4.  Access with evidence development in the UK: past experience, current initiatives and future potential.

Authors:  Andrew Briggs; Karen Ritchie; Elisabeth Fenwick; Kalipso Chalkidou; Peter Littlejohns
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Exploring uncertainty in cost-effectiveness analysis.

Authors:  Karl Claxton
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 6.  Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.

Authors:  Tania Stafinski; Christopher J McCabe; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 7.  When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.

Authors:  Louise Longworth; Jihee Youn; Laura Bojke; Stephen Palmer; Susan Griffin; Eldon Spackman; Karl Claxton
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

8.  SUPPORT Tools for evidence-informed health Policymaking (STP) 17: Dealing with insufficient research evidence.

Authors:  Andrew D Oxman; John N Lavis; Atle Fretheim; Simon Lewin
Journal:  Health Res Policy Syst       Date:  2009-12-16

9.  Making clinical trials more relevant: improving and validating the PRECIS tool for matching trial design decisions to trial purpose.

Authors:  Kirsty Loudon; Merrick Zwarenstein; Frank Sullivan; Peter Donnan; Shaun Treweek
Journal:  Trials       Date:  2013-04-27       Impact factor: 2.279
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.